Citation: Chunying Li, Yifan Zhang, Yilin Wan, Jingle Wang, Jing Lin, Zhiming Li, Peng Huang. STING-activating drug delivery systems: Design strategies and biomedical applications[J]. Chinese Chemical Letters, ;2021, 32(5): 1615-1625. doi: 10.1016/j.cclet.2021.01.001 shu

STING-activating drug delivery systems: Design strategies and biomedical applications

Chunying Li ^{a, b, 1} ,
Yifan Zhang ^{b, 1} ,
Yilin Wan ^b ,
Jingle Wang ^c ,
Jing Lin ^b ,
Zhiming Li ^{a, *,} ,
Peng Huang ^{a, b, *,}

a.
Department of Dermatology and Venereology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
b.
Marshall Laboratory of Biomedical Engineering, International Cancer Center, Laboratory of Evolutionary Theranostics (LET), School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen 518060, China
c.
Department of Medical Oncology, The Third Affiliated Hospital of Shanghai University, Wenzhou 325000, China

zhi-mingli@163.com

huang@szu.edu.cn

Received Date: 3 November 2020
Revised Date: 4 January 2021
Accepted Date: 4 January 2021
Available Online: 8 January 2021

Figures(9)

The stimulator of interferon genes (STING) shows promising clinical activity in infectious diseases and tumors. However, the lack of targeting capability and intracellular stability of STING agonists severely limits the therapeutic efficacy. Recently, drug delivery systems (DDSs) overcome these delivery barriers of STING agonists via passive or active cell targeting, prolonged blood circulation and drug release, and lysosome escape, etc. In this review, we will describe in detail how existing DDSs are designed to overcome delivery barriers and activate the STING pathway, and the current biomedical applications of STING-activating DDSs in the treatments of infectious diseases and tumors. Finally, the prospects and challenges of DDSs in STING activation are discussed.
- STING agonist,
- Drug delivery system,
- Cancer treatment,
- Anti-virus treatment,
- Immunotherapy
1. [1]
  H. Erratum, G.N. Barber, Nature 456(2008) 274.
2. [2]
  F.V. Marinho, S. Benmerzoug, S.C. Oliveira, B. Ryffel, V.F.J. Quesniaux, Trends Microbiol. 25(2017) 906-918. doi: 10.1016/j.tim.2017.05.008
3. [3]
  K.P. Hopfner, V. Hornung, Nat. Rev. Mol. Cell Bio. 21(2020) 501-521. doi: 10.1038/s41580-020-0244-x
4. [4]
  Z. Cheng, T. Dai, X. He, et al., Signal Transduct. Target. Ther. 5(2020) 91. doi: 10.1038/s41392-020-0198-7
5. [5]
  M. Motwani, S. Pesiridis, K.A. Fitzgerald, Nat. Rev. Genet. 20(2019) 657-674. doi: 10.1038/s41576-019-0151-1
6. [6]
  L. Corrales, V. Matson, B. Flood, S. Spranger, T.F. Gajewski, Cell Res. 27(2017) 96-108. doi: 10.1038/cr.2016.149
7. [7]
  G.N. Barber, Nat. Rev. Immunol. 15(2015) 760-770. doi: 10.1038/nri3921
8. [8]
  L. Corrales, L.H. Glickman, S.M. McWhirter, et al., Cell Rep. 11(2015) 1018-1030. doi: 10.1016/j.celrep.2015.04.031
9. [9]
  J. Zhang, Y. Chen, X. Chen, et al., Cell Death Differ. 28(2020) 139-155.
10. [10]
  A. Poh, Cancer Discov. 8(2018) 259-260. doi: 10.1158/2159-8290.CD-ND2018-002
11. [11]
  A. Naing, J.F. Gainor, H. Gelderblom, et al., J. Immunother. Cancer 8(2020) e000530. doi: 10.1136/jitc-2020-000530
12. [12]
  W. Deng, A.L. Desbien, K.S. Gauthier, et al., Cancer Immunol. Res. 8(2020) PR09.
13. [13]
  T.W. Dubensky, D.B. Kanne, M.L. Leong, Rationale, Ther. Adv. Vaccines 1(2013) 131-143. doi: 10.1177/2051013613501988
14. [14]
  D. Shae, K.W. Becker, P. Christov, et al., Nat. Nanotech. 14(2019) 269-278. doi: 10.1038/s41565-018-0342-5
15. [15]
  M.C. Hanson, M.P. Crespo, W. Abraham, et al., J. Clin. Invest. 125(2015) 2532-2546. doi: 10.1172/JCI79915
16. [16]
  A. Kakkar, G. Traverso, O.C. Farokhzad, et al., Nat. Rev. Chem. 1(2017) 0063. doi: 10.1038/s41570-017-0063
17. [17]
  J. Li, D.J. Mooney, Nat. Rev. Mater. 1(2016) 16071. doi: 10.1038/natrevmats.2016.71
18. [18]
  S.L. Huang, Adv. Drug Del. Rev. 60(2008) 1167-1176. doi: 10.1016/j.addr.2008.03.003
19. [19]
  G. Barouti, C.G. Jaffredo, S.M. Guillaume, Prog. Polym. Sci. 73(2017) 1-31. doi: 10.1016/j.progpolymsci.2017.05.002
20. [20]
  T. Su, Y. Zhang, K. Valerie, et al., Theranostics 9(2019) 7759-7771. doi: 10.7150/thno.37574
21. [21]
  D.R. Wilson, R. Sen, J.C. Sunshine, et al., Nanotechnol. Biol. Med. 14(2018) 237-246. doi: 10.1016/j.nano.2017.10.013
22. [22]
  E. Lee, H.E. Jang, Y.Y. Kang, et al., Acta Biomater. 29(2016) 271-281. doi: 10.1016/j.actbio.2015.10.025
23. [23]
  Y. Zhang, T. Shen, S. Zhou, et al., Adv. Ther. 41(2020) 2000083.
24. [24]
  S. Hong, P.R. Leroueil, E.K. Janus, et al., Bioconjug. Chem. 17(2006) 728-734. doi: 10.1021/bc060077y
25. [25]
  J. Fang, W. Islam, H. Maeda, Adv. Drug Del. Rev. 157(2020) 142-160. doi: 10.1016/j.addr.2020.06.005
26. [26]
  S. Patel, J. Kim, M. Herrera, et al., Adv. Drug Del. Rev. 144(2019) 90-111. doi: 10.1016/j.addr.2019.08.004
27. [27]
  T.T. Smith, H.F. Moffett, S.B. Stephan, et al., J. Clin. Invest. 127(2017) 2176-2191. doi: 10.1172/JCI87624
28. [28]
  J. Wang, P. Li, Y. Yu, et al., Science 367(2020) eaau0810. doi: 10.1126/science.aau0810
29. [29]
  Y. Liu, W.N. Crowe, L. Wang, et al., Nat. Commun. 10(2019) 5108. doi: 10.1038/s41467-019-13094-5
30. [30]
  S.T. Koshy, A.S. Cheung, L. Gu, et al., Adv. Biosys. 1(2017) 1600013. doi: 10.1002/adbi.201600013
31. [31]
  T. Nakamura, H. Miyabe, M. Hyodo, et al., J. Control. Release 216(2015) 149-157. doi: 10.1016/j.jconrel.2015.08.026
32. [32]
  Y. Sato, H. Hatakeyama, Y. Sakurai, et al., J. Control. Release 163(2012) 267-276. doi: 10.1016/j.jconrel.2012.09.009
33. [33]
  L.C.W. Lin, C.Y. Huang, B.Y. Yao, et al., Adv. Funct. Mater. 29(2019) 1807616. doi: 10.1002/adfm.201807616
34. [34]
  R.D. Junkins, M.D. Gallovic, B.M. Johnson, et al., J. Control. Release 270(2018) 1-13. doi: 10.1016/j.jconrel.2017.11.030
35. [35]
  M.A. Collier, R.D. Junkins, M.D. Gallovic, et al., Mol. Pharm. 15(2018) 4933-4946. doi: 10.1021/acs.molpharmaceut.8b00579
36. [36]
  M. Luo, H. Wang, Z. Wang, et al., Nat. Nanotech. 12(2017) 648-654. doi: 10.1038/nnano.2017.52
37. [37]
  L. Hou, C. Tian, Y. Yan, et al., ACS Nano 14(2020) 3927-3940. doi: 10.1021/acsnano.9b06111
38. [38]
  Y. He, C. Hong, E.Z. Yan, et al., Sci. Adv. 6(2020) eaba7589. doi: 10.1126/sciadv.aba7589
39. [39]
  C.G. Park, C.A. Hartl, D. Schmid, et al., Sci. Transl. Med. 10(2018) 1-14.
40. [40]
  D.G. Leach, N. Dharmaraj, S.L. Piotrowski, et al., Biomaterials 163(2018) 67-75. doi: 10.1016/j.biomaterials.2018.01.035
41. [41]
  M. Manzano, M. Vallet-Regí, Adv. Funct. Mater. 30(2020) 1902634.
42. [42]
  H. Maeda, J. Wu, T. Sawa, et al., J. Control. Release 65(2000) 271-284. doi: 10.1016/S0168-3659(99)00248-5
43. [43]
  H. Chen, W. Zhang, G. Zhu, J. Xie, X. Chen, Nat. Rev. Mater. 2(2017) 17024. doi: 10.1038/natrevmats.2017.24
44. [44]
  P. Saftig, A. Haas, Nat. Cell Biol. 18(2016) 1025-1027. doi: 10.1038/ncb3409
45. [45]
  J. Huotari, A. Helenius, EMBO J. 30(2011) 3481-3500. doi: 10.1038/emboj.2011.286
46. [46]
  J.K. Vasir, V. Labhasetwar, Adv. Drug Del. Rev. 59(2007) 718-728. doi: 10.1016/j.addr.2007.06.003
47. [47]
  S. Yildiz, E. Alpdundar, B. Gungor, et al., Eur. J. Immunol. 45(2015) 1170-1179. doi: 10.1002/eji.201445133
48. [48]
  R.V. Benjaminsen, M.A. Mattebjerg, J.R. Henriksen, et al., Mol. Ther. 21(2013) 149-157. doi: 10.1038/mt.2012.185
49. [49]
  D.U. Lee, J.Y. Park, S. Kwon, et al., Nanoscale 11(2019) 19980-19993. doi: 10.1039/C9NR04323C
50. [50]
  P.K. Tegtmeyer, J. Spanier, K. Borst, et al., Nat. Commun. 10(2019) 2830. doi: 10.1038/s41467-019-10863-0
51. [51]
  L. Kraft, T. Erdenesukh, M. Sauter, C. Tschöpe, K. Klingel, Basic Res. Cardiol. 114(2019) 11.
52. [52]
  T. Lu, F. Hu, H. Yue, T. Yang, G. Ma, J. Control. Release 321(2020) 576-588. doi: 10.1016/j.jconrel.2020.02.039
53. [53]
  S. Chattopadhyay, Y.H. Liu, Z.S. Fang, et al., Nano Lett. 20(2020) 2246-2256. doi: 10.1021/acs.nanolett.9b04094
54. [54]
  N. Cheng, R. Watkins-Schulz, R.D. Junkins, et al., JCI Insight 3(2018) e120638. doi: 10.1172/jci.insight.120638
55. [55]
  M. An, C. Yu, J. Xi, et al., Nanoscale 10(2018) 9311-9319. doi: 10.1039/C8NR01376D
56. [56]
  J. Fu, D.B. Kanne, M. Leong, et al., Sci. Transl. Med. 7(2015) 283ra252.
57. [57]
  L. Wang-Bishop, M. Wehbe, D. Shae, et al., J. Immunother. Cancer 8(2020) e000282. doi: 10.1136/jitc-2019-000282
58. [58]
  H. Miyabe, M. Hyodo, T. Nakamura, et al., Release 184(2014) 20-27. doi: 10.1016/j.jconrel.2014.04.004
59. [59]
  G. Reina, S. Peng, L. Jacquemin, A.F. Andrade, A. Bianco, ACS Nano 14(2020) 9364-9388. doi: 10.1021/acsnano.0c04117
60. [60]
  L. Deng, B.Z. Wang, ACS Infect. Dis. 4(2018) 1656-1665. doi: 10.1021/acsinfecdis.8b00206
61. [61]
  V.N. Petrova, C.A. Russell, Nat. Rev. Microbiol. 16(2018) 47-60. doi: 10.1038/nrmicro.2017.118
62. [62]
  L.D. Estrada, S. Schultz-Cherry, J. Immunol. 202(2019) 392.
63. [63]
  D. Lavanchy, J. Viral Hepat. 11(2004) 97-107. doi: 10.1046/j.1365-2893.2003.00487.x
64. [64]
  G.V. Papatheodoridis, T. Voulgaris, M. Papatheodoridi, W.R. Kim, Hepatology (2020), doi: http://dx.doi.org/10.1002/hep.31440.
65. [65]
  Y.F. Liaw, Nat. Rev. Gastro. Hepat. 16(2019) 631-641. doi: 10.1038/s41575-019-0197-8
66. [66]
  O. Al-Sahaf, J.H. Wang, T.J. Browne, T.G. Cotter, H.P. Redmond, Ann. Surg. 252(2010) 1037-1043. doi: 10.1097/SLA.0b013e3181efc635
67. [67]
  F.W. Abdallah, D.N. Wijeysundera, Lancet 394(2019) 1781-1782. doi: 10.1016/S0140-6736(19)32314-1
68. [68]
  D. De Ruysscher, G. Niedermann, N.G. Burnet, et al., Nat. Rev. Dis. Primers 5(2019) 13. doi: 10.1038/s41572-019-0064-5
69. [69]
  R.R. Weichselbaum, H. Liang, L. Deng, Y.X. Fu, Nat. Rev. Clin. Oncol. 14(2017) 365-379. doi: 10.1038/nrclinonc.2016.211
70. [70]
  S. Cerboni, N. Jeremiah, M. Gentili, et al., J. Exp. Med. 214(2017) 1769-1785. doi: 10.1084/jem.20161674
71. [71]
  F. Zhou, B. Feng, H. Yu, et al., Adv. Mater. 31(2019) 1805888. doi: 10.1002/adma.201805888
72. [72]
  L. Galluzzi, G. Petroni, G. Kroemer, J. Immunother. Cancer 8(2020) e000802. doi: 10.1136/jitc-2020-000802
73. [73]
  K.N. Dzhandzhugazyan, P. Guldberg, A.F. Kirkin, Nat. Mater. 17(2018) 475-477. doi: 10.1038/s41563-018-0094-5
74. [74]
  S. Crunkhorn, Nat. Rev. Drug Discov. 17(2018) 242.
75. [75]
  N. Auslander, G. Zhang, J.S. Lee, et al., Nat. Med. 24(2018) 1545-1549. doi: 10.1038/s41591-018-0157-9
76. [76]
  A.B. Warner, J.S. Palmer, A.N. Shoushtari, et al., J. Clin. Oncol. 38(2020) 1655-1663. doi: 10.1200/JCO.19.01464
77. [77]
  A. Yip, R.M. Webster, Nat. Rev. Drug Discov. 17(2018) 161-162. doi: 10.1038/nrd.2017.266
78. [78]
  J. Ahn, H. Konno, G.N. Barber, Oncogene 34(2015) 5302-5308. doi: 10.1038/onc.2014.457
79. [79]
  T. Xia, H. Konno, G.N. Barber, Cancer Res. 76(2016) 6747-6759. doi: 10.1158/0008-5472.CAN-16-1404
80. [80]
  Y. Tang, X. Wang, J. Li, et al., ACS Nano 13(2019) 13015-13026. doi: 10.1021/acsnano.9b05679
81. [81]
  S. El Andaloussi, I. Mäger, X.O. Breakefield, M.J.A. Wood, Nat. Rev. Drug Discov. 12(2013) 347-357. doi: 10.1038/nrd3978
82. [82]
  S.C. Jang, O.Y. Kim, C.M. Yoon, et al., ACS Nano 7(2013) 7698-7710. doi: 10.1021/nn402232g
83. [83]
  O.Y. Kim, S.J. Choi, S.C. Jang, et al., Nano Lett. 15(2015) 266-274. doi: 10.1021/nl503508h
84. [84]
  J.P. Stone, D.D. Wagner, J. Clin. Invest. 92(1993) 804-813. doi: 10.1172/JCI116654
85. [85]
  X. Zhang, C. Wang, J. Wang, et al., Adv. Mater. 30(2018) 1707112. doi: 10.1002/adma.201707112
86. [86]
  X. Han, S. Shen, Q. Fan, et al., Sci. Adv. 5(2019) 1-9.
87. [87]
  J. Dobbins, E. Gagnon, J. Godec, et al., Sci. Signal. 9(2016) ra75. doi: 10.1126/scisignal.aaf0626
88. [88]
  S.S. Lucky, K.C. Soo, Y. Zhang, et al., Chem. Rev. 115(2015) 1990-2042. doi: 10.1021/cr5004198
89. [89]
  A. Master, M. Livingston, A. Sen Gupta, J. Control. Release 168(2013) 88-102. doi: 10.1016/j.jconrel.2013.02.020
90. [90]
  D.K.R. Karaolis, M.H. Rashid, R. Chythanya, et al., Antimicrob. Agents Ch. 49(2005) 1029. doi: 10.1128/AAC.49.3.1029-1038.2005
91. [91]
  D.L. Hu, K. Narita, M. Hyodo, et al., Vaccine 27(2009) 4867-4873. doi: 10.1016/j.vaccine.2009.04.053
92. [92]
  P.M. Gray, G. Forrest, T. Wisniewski, et al., Cell. Immunol. 278(2012) 113-119. doi: 10.1016/j.cellimm.2012.07.006
93. [93]
  K.O. Ramberg, P.M. Antonik, D.L. Cheung, P.B. Crowley, Bioconjug. Chem. 30(2019) 1162-1168. doi: 10.1021/acs.bioconjchem.9b00099
94. [94]
  J. Wang, H. Wang, H. Cui, et al., Chin. Chem. Lett. 31(2020) 3143-3148. doi: 10.1016/j.cclet.2020.07.027
95. [95]
  Y. Zhang, K. Huang, J. Lin, P. Huang, Biomater. Sci. 7(2019) 1262-1275. doi: 10.1039/C8BM01523F
96. [96]
  Y.N. Zhang, J. Lazarovits, W. Poon, et al., Nano Lett. 19(2019) 7226-7235. doi: 10.1021/acs.nanolett.9b02834
1. [1]
  Yujie Li , Ya-Nan Wang , Yin-Gen Luo , Hongcai Yang , Jinrui Ren , Xiao Li . Advances in synthetic biology-based drug delivery systems for disease treatment. Chinese Chemical Letters, 2024, 35(11): 109576-. doi: 10.1016/j.cclet.2024.109576
2. [2]
  Qiang Li , Jiangbo Fan , Hongkai Mu , Lin Chen , Yongzhen Yang , Shiping Yu . Nucleus-targeting orange-emissive carbon dots delivery adriamycin for enhanced anti-liver cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108947-. doi: 10.1016/j.cclet.2023.108947
3. [3]
  Zhilong Xie , Guohui Zhang , Ya Meng , Yefei Tong , Jian Deng , Honghui Li , Qingqing Ma , Shisong Han , Wenjun Ni . A natural nano-platform: Advances in drug delivery system with recombinant high-density lipoprotein. Chinese Chemical Letters, 2024, 35(11): 109584-. doi: 10.1016/j.cclet.2024.109584
4. [4]
  Yanfei Liu , Yaqin Hu , Yifu Tan , Qiwen Chen , Zhenbao Liu . Tumor acidic microenvironment activatable DNA nanostructure for precise cancer cell targeting and inhibition. Chinese Chemical Letters, 2025, 36(1): 110289-. doi: 10.1016/j.cclet.2024.110289
5. [5]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
6. [6]
  Junjie Wang , Yan Wang , Zhengdong Li , Changqiang Xie , Musammir Khan , Xingzhou Peng , Fabiao Yu . Triphenylamine-AIEgens photoactive materials for cancer theranostics. Chinese Chemical Letters, 2024, 35(6): 108934-. doi: 10.1016/j.cclet.2023.108934
7. [7]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
8. [8]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
9. [9]
  Shuheng Zhang , Yuanyuan Zhang , Wanyu Wang , Yuzhu Hu , Xinchuan Chen , Bilan Wang , Xiang Gao . A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy. Chinese Chemical Letters, 2024, 35(12): 109658-. doi: 10.1016/j.cclet.2024.109658
10. [10]
  Chenlu Huang , Xinyu Yang , Qingyu Yu , Linhua Zhang , Dunwan Zhu . Gas-generating polymersomes-based amplified photoimmunotherapy for abscopal effect and tumor metastasis inhibition. Chinese Chemical Letters, 2024, 35(6): 109680-. doi: 10.1016/j.cclet.2024.109680
11. [11]
  Xinyue Lan , Junguang Liang , Churan Wen , Xiaolong Quan , Huimin Lin , Qinqin Xu , Peixian Chen , Guangyu Yao , Dan Zhou , Meng Yu . Photo-manipulated polyunsaturated fatty acid-doped liposomal hydrogel for flexible photoimmunotherapy. Chinese Chemical Letters, 2024, 35(4): 108616-. doi: 10.1016/j.cclet.2023.108616
12. [12]
  Bohan Chen , Liming Gong , Jing Feng , Mingji Jin , Liqing Chen , Zhonggao Gao , Wei Huang . Research advances of nanoparticles for CAR-T therapy in solid tumors. Chinese Chemical Letters, 2024, 35(9): 109432-. doi: 10.1016/j.cclet.2023.109432
13. [13]
  Tong Tong , Lezong Chen , Siying Wu , Zhong Cao , Yuanbin Song , Jun Wu . Establishment of a leucine-based poly(ester amide)s library with self-anticancer effect as nano-drug carrier for colorectal cancer treatment. Chinese Chemical Letters, 2024, 35(12): 109689-. doi: 10.1016/j.cclet.2024.109689
14. [14]
  Haijing Cui , Weihao Zhu , Chuning Yue , Ming Yang , Wenzhi Ren , Aiguo Wu . Recent progress of ultrasound-responsive titanium dioxide sonosensitizers in cancer treatment. Chinese Chemical Letters, 2024, 35(10): 109727-. doi: 10.1016/j.cclet.2024.109727
15. [15]
  Yiran Tao , Chunlei Dai , Zhaoxiang Xie , Xinru You , Kaiwen Li , Jun Wu , Hai Huang . Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer. Chinese Chemical Letters, 2024, 35(8): 109170-. doi: 10.1016/j.cclet.2023.109170
16. [16]
  Dexuan Xiao , Tianyu Chen , Tianxu Zhang , Sirong Shi , Mei Zhang , Xin Qin , Yunkun Liu , Longjiang Li , Yunfeng Lin . Transdermal treatment for malignant melanoma by aptamer-modified tetrahedral framework nucleic acid delivery of vemurafenib. Chinese Chemical Letters, 2024, 35(4): 108602-. doi: 10.1016/j.cclet.2023.108602
17. [17]
  Yunjie Dang , Yanru Feng , Xiao Chen , Chaoxing He , Shujie Wei , Dingyang Liu , Jinlong Qi , Huaxing Zhang , Shaokun Yang , Zhiyun Niu , Bai Xiang . Development of a multi-level pH-responsive lipid nanoplatform for efficient co-delivery of siRNA and small-molecule drugs in tumor treatment. Chinese Chemical Letters, 2024, 35(12): 109660-. doi: 10.1016/j.cclet.2024.109660
18. [18]
  Wenjia Wang , Xingyue He , Xiaojie Wang , Tiantian Zhao , Osamu Muraoka , Genzoh Tanabe , Weijia Xie , Tianjiao Zhou , Lei Xing , Qingri Jin , Hulin Jiang . Glutathione-depleted cyclodextrin pseudo-polyrotaxane nanoparticles for anti-inflammatory oxaliplatin (Ⅳ) prodrug delivery and enhanced colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(4): 108656-. doi: 10.1016/j.cclet.2023.108656
19. [19]
  Shuyu Liu , Xiaomin Sun , Bohan Song , Gaofeng Zeng , Bingbing Du , Chongshen Guo , Cong Wang , Lei Wang . Design and Fabrication of Phospholipid-Vesicle-based Artificial Cells towards Biomedical Applications. University Chemistry, 2024, 39(11): 182-188. doi: 10.12461/PKU.DXHX202404113
20. [20]
  Zhigang Zeng , Changzhou Liao , Lei Yu . Molecules for COVID-19 treatment. Chinese Chemical Letters, 2024, 35(7): 109349-. doi: 10.1016/j.cclet.2023.109349

Get Citation

PDF

XML

Metrics

PDF Downloads(16)
Abstract views(1132)
HTML views(169)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142